Key result
7-Ketolithocholic acid reduces creatinine and BUN in renal fibrosis models via TGF-β/Smad and Wnt/β-catenin inhibition.
Why the study?
The study was conducted to explore the protective effects of 7-ketolithocholic acid against renal fibrosis and its mechanism, focusing on its interaction with farnesoid X receptor.
Does 7-Ketolithocholic acid reduce renal fibrosis in preclinical models?
Does 7-Ketolithocholic acid reduce renal fibrosis in preclinical models?
7-KLCA exerts anti-renal fibrotic effects by targeting FXR and suppressing the TGF-β/Smad and Wnt/β-catenin pathways in preclinical models.
Background/Objectives: To explore the protective effects of 7-Ketolithocholic acid (7-KLCA) against renal fibrosis and its mechanism, focusing on its interaction with farnesoid X receptor (FXR). Methods: In vitro, TGF-β-induced fibrosis in HK-2/NRK-49F cells and LPS-induced inflammation in HK-2 cells were detected by CCK-8, Western blot, and qPCR. In vivo, unilateral ureteral obstruction (UUO) and adenine (Ade)-induced mouse models were treated with a low/high-dose 7-KLCA or losartan. Renal injury was evaluated via H&E/Masson staining, serum creatinine (SCR), and blood urea nitrogen (BUN) levels. The 7-KLCA-FXR interaction was verified by molecular docking, CETSA, and DARTS. FXR downstream genes and related proteins were measured by WB and qPCR. Results: 7-KLCA inhibited the expression of fibrotic proteins (fibronectin, collagen-I) and reduced the LPS-induced release of inflammatory factors (IL-1β, IL-6). In mice, it alleviated renal swelling, collagen deposition, and tubular damage, while lowering serum SCR and BUN levels. Mechanistically, 7-KLCA stably bound to the FXR ligand-binding domain, enhanced its thermal stability and degradation resistance. It upregulated FXR and its downstream genes SHP and FGF15, thereby inhibiting the activation of TGF-β/Smad and Wnt/β-catenin pathways. Conclusions: This is the first study to clarify the molecular mechanism through which 7-KLCA targets FXR and dually suppresses the key pro-fibrotic pathways TGF-β/Smad and Wnt/β-catenin, thereby exerting anti-renal fibrosis effects.
No takes yet. Share an insight, caveat, or question.
Guo et al. (2025) studied this question. 7-Ketolithocholic acid significantly reduced serum creatinine and blood urea nitrogen levels while inhibiting TGF-β/Smad and Wnt/β-catenin pathways in renal fibrosis models.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: